GENE ONLINE|News &
Opinion
Blog

2020-08-31| In-DepthR&DSpecial

Spotlight: Infusion-Related Reactions Associated with Rapid Infusion of Daratumumab

by GeneOnline
Share To
Daratumumab, an anti-CD38 monoclonal antibody, has revolutionized the treatment outcome and prognostic expectations in patients with relapsed myeloma. The USFDA approved it in November 2015 for treating patients with relapsed refractory multiple myeloma (RRMM) and those with newly diagnosed multiple myeloma (MM) who are ineligible for stem cell transplant.

Daratumumab, as the newest class of therapeutics for MM, has demonstrated substantial clinical efficacy and rapid and durable response in patients with RRMM who relapse after initial therapy or are refractory to immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) [1,2].

GO Prime with only $1.49 now

LATEST
Ginkgo Bioworks and Pfizer Forge $331 Million Collaboration for RNA-Based Drug Discovery
2023-09-29
Johnson & Johnson Partners with Singapore to Boost Life Sciences Innovation
2023-09-28
Vietnam and South Korea Strengthen Cooperation in Multiple Sectors
2023-09-27
PeptiDream and Genentech Collaborate on Novel Peptide-Radioisotope Drug Conjugates
2023-09-27
AcuraStem and Takeda Collaborate on Innovative ALS Treatment
2023-09-27
Seven AI/ML for Life Sciences Companies Identified as Innovators in New Clarivate Companies to Watch Report
2023-09-27
GeneOnline’s Weekly News Highlights: Sept 17-Sept 22
2023-09-26
EVENT
2023-10-04
BioFuture 2023
New York city,USA
Scroll to Top